Clinical Scorecard: Assessment of Liver Fibrosis Alterations Following DAA Treatment for Hepatitis C in Individuals With and Without HIV: Findings from the ACTG A5320 Long-Term Cohort Study on Viral Hepatitis C (VHICS)

At a Glance

Key Highlights

• ELF identified advanced liver fibrosis more frequently than APRI or FIB-4 at study entry post-HCV cure.
• Advanced fibrosis by ELF did not significantly decrease over 5 years despite decreases in APRI and FIB-4 early after treatment.
• HCV/HIV co-infected participants had nearly double the risk of clinical events compared to HCV-only participants.

Guideline-Based Recommendations

Diagnosis

• Use ELF as a direct marker of liver fibrosis for more accurate assessment post-HCV cure compared to APRI and FIB-4.
• Monitor fibrosis using multiple markers including APRI, FIB-4, and ELF at baseline and semiannually after DAA treatment.

Management

• Continue long-term monitoring of liver fibrosis and clinical events after SVR, especially in patients with advanced fibrosis by ELF.
• Recognize higher risk of clinical events in HCV/HIV co-infected individuals and tailor follow-up accordingly.

Monitoring & Follow-up

• Perform semiannual assessments of liver fibrosis markers (APRI, FIB-4, ELF) for up to 5 years post-treatment.
• Include clinical event surveillance focusing on liver-related diagnoses and all-cause mortality.

Risks

• Advanced fibrosis detected by ELF is associated with increased risk of liver-related clinical events and death.
• HIV co-infection increases risk of adverse clinical outcomes after HCV cure.

Patient & Prescribing Data

Individuals with sustained virologic response after DAA-based HCV treatment, with and without HIV co-infection

DAA therapy leads to early decreases in APRI and FIB-4 likely due to reduced necroinflammation, but ELF detects persistent advanced fibrosis which correlates with clinical outcomes.

Clinical Best Practices

• Incorporate ELF testing alongside APRI and FIB-4 for comprehensive fibrosis assessment post-HCV cure.
• Maintain long-term follow-up for liver fibrosis and clinical events, especially in patients with advanced fibrosis or HIV co-infection.
• Use fibrosis marker thresholds (ELF ≥9.8 for advanced fibrosis) to stratify risk and guide monitoring intensity.
• Consider insulin resistance assessment (HOMA-IR) as part of metabolic evaluation in this population.

References

• ACTG A5320 VHICS Study Primary Manuscript
• Enhanced Liver Fibrosis (ELF) Test Validation
• Fibrosis Markers APRI and FIB-4 Definitions